Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | PolyPid files for secondary offering | 1 | Seeking Alpha | ||
17.01. | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
26.12.24 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
24.12.24 | PolyPid Ltd.: PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients with a Concurrent Private Placement of up to $41 Million | 96 | GlobeNewswire (Europe) | • 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a... ► Artikel lesen | |
11.12.24 | PolyPid stock hits 52-week low at $2.81 amid market challenges | 2 | Investing.com | ||
11.12.24 | PolyPid-Aktie erreicht 52-Wochen-Tief bei 2,81 US-Dollar | - | Investing.com Deutsch | ||
POLYPID Aktie jetzt für 0€ handeln | |||||
11.12.24 | PolyPid enters R&D pact with ImmunoGenesis | 2 | Investing.com | ||
11.12.24 | PolyPid Ltd.: PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy | 1 | GlobeNewswire (USA) | ||
11.12.24 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
04.12.24 | PolyPid stock touches 52-week low at $2.93 amid market challenges | 2 | Investing.com | ||
02.12.24 | PolyPid receives Nasdaq's non-compliance letter | 1 | Seeking Alpha | ||
29.11.24 | PolyPid Ltd.: PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance | 1.259 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced... ► Artikel lesen | |
29.11.24 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
13.11.24 | PolyPid reports 9M results | 1 | Seeking Alpha | ||
12.11.24 | PolyPid's Earnings: A Preview | 1 | Benzinga.com | ||
08.11.24 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
04.11.24 | PolyPid-Aktien steigen aufgrund vielversprechender Phase-3-Aussichten und erhalten Kaufempfehlung | 1 | Investing.com Deutsch | ||
04.11.24 | PolyPid shares rise on strong Phase 3 prospects, gets buy rating | 3 | Investing.com | ||
30.10.24 | PolyPid Ltd.: PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 | 1 | GlobeNewswire (USA) | ||
21.10.24 | PolyPid Ltd.: PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX100 in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 116,10 | -0,94 % | BioNTech Aktie: Geplante Maßnahmen und Strategien | Die BioNTech-Aktie zeigt sich in den ersten Januarwochen 2025 weitgehend stabil. Am Handelstag des 18. Januar verzeichnete das Papier einen leichten Rückgang von 0,74 Prozent auf 111,93 USD. Die Marktkapitalisierung... ► Artikel lesen | |
EVOTEC | 8,200 | +3,67 % | Evotec: Verkaufswelle hat begonnen | Der Preis der Evotec-Aktie sinkt. Dieser Kursrückgang findet gesittet statt, ohne dabei die Anleger zu verschrecken. Manch einer hofft noch auf steigende Kurse. Doch das Chartbild spricht eine andere... ► Artikel lesen | |
CUREVAC | 3,756 | -1,00 % | Schock-News für CureVac Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
AMGEN | 264,35 | -0,88 % | Amgen Aktie: Starkes Wachstum sichert Zukunft | Die Amgen Aktie zeigt sich zum Jahresstart 2025 in robuster Verfassung. Der Biotechnologie-Konzern verzeichnete am 18. Januar einen Kursanstieg von 0,99% auf 272,11 USD. Besonders bemerkenswert ist... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
DEFENCE THERAPEUTICS | 0,550 | +4,56 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,384 | -4,00 % | Biotech-Perle 2025! Hat dieses Unternehmen die "Neuronale Universalwaffe"? | ||
IBIO | 3,040 | 0,00 % | iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio | SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development... ► Artikel lesen | |
ARROWHEAD PHARMACEUTICALS | 20,550 | -0,63 % | AKTIONÄR-Favorit Arrowhead Pharmaceuticals: Wichtiger Meilenstein | Gute Nachrichten von Arrowhead Pharmaceuticals am Freitagabend. Die US-Gesundheitsbehörde FDA hat den Antrag auf Marktzulassung des Unternehmens für Plozasiran zur Behandlung von Patienten mit einer... ► Artikel lesen | |
COHERUS | 1,333 | +7,20 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen | |
VOYAGER THERAPEUTICS | 5,220 | -1,88 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2024 Financial and Operating Results | - Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data... ► Artikel lesen | |
OPGEN | 0,438 | +7,35 % | OPGEN INC - 8-K, Current Report | ||
MEREO BIOPHARMA | 3,200 | +8,11 % | Mereo BioPharma Group plc - S-8, Securities to be offered to employees in employee benefit plans | ||
BENITEC BIOPHARMA | 10,800 | 0,00 % | Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update | -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical... ► Artikel lesen | |
CYBIN | 9,900 | +1,54 % | Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results | TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare... ► Artikel lesen |